



NCI-FREDERICK  
INSTITUTIONAL BIOSAFETY COMMITTEE

Minutes  
June 16, 2009  
NCI-Frederick

## **INTRODUCTION**

The NCI-Frederick Institutional Biosafety Committee was convened at 12:06 p.m. in the Building 549 Executive Board Room with the following members in attendance:

Dr. Randall Morin, Chair; Ms. Theresa Bell, IBC Secretary and Biosafety Officer; Dr. Stephen Creekmore; Dr. David Garfinkel; Dr. Serguei Kozlov; Ms. Dianna Conrad; Dr. Bruce Crise; Dr. David Derse; Dr. Eric Freed; Mr. Lucien Winegar

Members not in attendance: Mr. Scott Jendrek; Ms. Alberta Peugeot; Dr. Michael Baseler; Dr. Henry Hearn; Dr. Melinda Hollingshead; Dr. Stephen Hughes; Dr. Dan McVicar

Others in attendance: Dr. Scott Keimig; Reverend David Betzner; Dr. Robert Thomas; Ms. Karen Barber; Ms. Sarah Hooper

Dr. Morin requested a motion to vote-in Reverend Betzner as an IBC community member. Mr. Winegar made the motion, Dr. Garfinkel seconded and all were in favor.

## **MINUTES**

-May 2009 minutes will be distributed for review and approval through email.

## **REVIEW OF PROTOCOLS**

## **NEW IBC REGISTRATIONS**

### **09-23 (Dr. Anver) Support services on the behalf of NCI investigators in PHL.**

-Updates were provided to the committee stating that the PI was working on revisions to the registration to compose two independent IBC documents, one addressing human samples and one addressing animal samples. The lead reviewers have been working with the PI independently to assist PHL with this process. Revised documents will be reviewed as they are received by the IBC lead reviewers and will be brought back to full committee for review if necessary.

**09-31 (Dr. Klar) Developing a mouse model to study selective chromatid segregation phenomenon in vivo.**

-The lead reviewers have provided comments for the PI's consideration. A response has not yet been received.

*Dr. Freed made a motion to conditionally approve the registration pending receipt, review and acceptance of the PI responses, Dr. Crise seconded and all were in favor.*

**09-32 (Dr. McMahan) Targeting carcinoma-associated fibroblasts.**

-This study involves pipetting via robotics into human material in very small quantities. It is debatable as to if engineering controls should be required.

-Does the manufacturer have an adapter or device to provide any engineering controls needed? Does the manufacturer recommend the use of an engineering control when using this device in conjunction with human material?

-Will gowning and other personal protective equipment be worn during operations?

-Has a demonstration been performed using riboflavin or other fluorescing material to determine if aerosolization is a problem?

-What are the costs of the machine and the engineering controls (are the costs warranted in comparison to the actual hazards posed by doing the work without them)?

*A motion for a vote was deferred at this time pending further discussion of the items above.*

**RENEWALS – None.**

**AMENDMENTS**

**06-101 (Pinto)**

-The lead reviewer (Dr. Crise) is working with Dr. Pinto's lab staff to clarify questions regarding the use of L1 (non-infectious) and L1 and L2 (infectious) particles for research with HPV. No approval may be issued at this time.

**07-64 (Swing) – Currently under review.**

**08-47 (Difilippantonio) – Currently under review.**

**OUTSTANDING ITEMS**

**09-13 (Hartley/Taylor)**-Pending receipt of edited registration from PI.

-This registration involves the use of E. coli strain BL-21. This strain is an attenuated laboratory strain and hence, does not pose a significant pathogen issue. However, a request to inspect current laboratory facilities was made by the IBC. Further discussions involving classification of hazardous materials used in this lab between Biosafety Level 1 and Biosafety Level 2 and if, the large-scale volumes used, required an upgrade in BSL requirements for facilities, practices and procedures. PEL is currently working on updating their SOP's to include a spill SOP for large-scale activities. An IBC sub-committee will convene to further discuss these issues.

**09-06 (Durum) – Approved by the lead reviewers June 16, 2009.**

**09-07 (Durum)** – PI to submit revisions.

**09-18 (Colburn/Young)** – PI to submit revisions.

**OTHER BUSINESS**

**BBP Compliance:** 95%

**OHS Accident Update:**

2 needlesticks were reported by Ms. Sarah Hooper, OHS.

**Human Pathogen Screen Update:**

-Dr. Reynolds recently approved the request from the IBC regarding the transition of the human pathogen screening testing services from the AHDL to the Molecular Detection Group within PEL. Ms. Bell will initiate contact with the appropriate personnel to assist with the transition process.

The meeting was adjourned at 12:55 p.m.

\_\_\_\_\_  
Theresa D. Bell, MPH, CBSP  
IBC Secretary  
Biological Safety Officer, EHS

\_\_\_\_\_  
Date

APPROVED:

\_\_\_\_\_  
Randall S. Morin, Dr. P.H.  
Chairman, NCI-Frederick IBC  
Director, EHS

\_\_\_\_\_  
Date

xc: Dr. Reynolds  
Mr. Wheatley  
Dr. Arthur  
Mr. Bufter